Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display

40P - Intra-tumoral CD3, CD4, and CD8 as prognostic biomarkers in Asian breast cancer

Date

02 Dec 2023

Session

Poster Display

Presenters

Jia Wern Pan

Citation

Annals of Oncology (2023) 34 (suppl_4): S1480-S1484. 10.1016/annonc/annonc1375

Authors

J.W. Pan1, H. Makmur1, P. Ng2, J. Tai1, S.N. Hasan2, C.H. Yip3, P. Rajadurai4, J. Lim2, S. Teo5

Author affiliations

  • 1 Genomics And Bioinformatics, Cancer Research Malaysia, 47500 - Subang Jaya/MY
  • 2 Core Laboratory, Cancer Research Malaysia, 47500 - Subang Jaya/MY
  • 3 Breast Surgery, Subang Jaya Medical Centre, 47500 - Subang Jaya/MY
  • 4 Pathology, Monash University, 47500 - Subang Jaya/MY
  • 5 Chief Scientific Officer, Cancer Research Malaysia, 47500 - Subang Jaya/MY

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 40P

Background

Recent evidence suggests that breast cancer may have population-specific characteristics, including differences in the tumour immune microenvironment (TME). Immune cell markers in the TME, particularly CD8, may have utility as predictive and prognostic biomarkers, but there is conflicting evidence from previous studies. The aim of this study was to determine the prognostic utility of immune cell immunohistochemistry markers in tumor samples from a cohort of breast cancer patients from Malaysia.

Methods

We obtained digitized whole slide images of breast tumour tissue samples stained for CD3, CD4, CD8, and PD-L1 markers for 576 breast cancer patients from Subang Jaya Medical Centre, a Malaysian private hospital. These patients were included in the Malaysian Breast Cancer (MyBrCa) study cohort, and thus multi-omics data were also available for analysis for each patient. We also obtained overall survival data from the Malaysian national registry for this group of patients, with a median follow-up time of 68 months.

Results

We compared the intra-tumoral scores for each marker to overall survival data and found that the scores for CD3, CD4, and CD8, but not PD-L1, were positively associated with overall survival, particularly for patients with triple-negative breast cancer (TNBC). Additionally, the CD3, CD4, and CD8 scores were not associated with tumour mutational burden (TMB) or neoantigen load and had a negative correlation with copy number aberrations.

Conclusions

Our results suggest that intra-tumoral markers for T-cells are indicative of good prognosis in Asian breast cancer. Our results also suggest that the TME in Asian breast cancer may be shaped by non-canonical pathways.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Cancer Research Malaysia.

Funding

Cancer Research Malaysia, Yayasan PETRONAS, Yayasan Sime Darby, Scientex Foundation, Estee Lauder Companies, Vistage Malaysia, Newton-Ungku Omar Fund.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.